4536 — Santen Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	—	—	—	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	249,605	266,257	279,037	301,965	300,004
Cost of Revenue
Gross Profit	151,384	156,586	166,087	178,709	171,027
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	237,410	228,890	282,425	264,302	253,841
Operating Profit	12,195	37,367	-3,388	37,663	46,163
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11,688	35,616	-5,799	29,874	47,481
Provision for Income Taxes
Net Income After Taxes	9,126	27,189	-14,983	26,703	35,853
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,311	27,218	-14,948	26,643	36,256
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	9,311	27,218	-14,955	26,642	36,256
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	72.7	65.3	26.3	109	109
Dividends per Share